News >

FDA Approval Sought for KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma

Gina Columbus @ginacolumbusonc
Published: Thursday, Dec 12, 2019

Ken Takeshita, MD, global head of Clinical Development, Kite

Ken Takeshita, MD

 A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma (MCL).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication